Dapagliflozin with LinagliptinGLIFIROZ-L TABLET

Glifiroz L combines Dapagliflozin (Sodium Glucose Type 2 inhibitor) and Linagliptin (Dipeptidyl Peptidase-4 inhibitor) for powerful dual-action glycemic control in type 2 diabetes. Dapagliflozin promotes urinary glucose excretion while aiding weight loss, blood pressure reduction, and cardiorenal protection. Linagliptin boosts incretin hormones to enhance insulin release and suppress glucagon with minimal hypoglycemia risk. This once-daily combination offers superior metabolic balance, high tolerability, and improved compliance—ideal for overweight, hypertensive, and elderly type 2 diabetes patients.

• Dosage:Once Daily with food OR as directed by the Physician
• Form: Tablet
• Indications:
  1. Diabetic Nephropathy
  2. Diabetes Mellitus type 2
  3. Heart failure
• Composition: Dapagliflozin 10 mg & Linagliptin 5 mg
• Mode of Action:Glifiroz L combines Dapagliflozin (sodium-glucose cotransporter type 2 inhibitor) and Linagliptin (Dipeptidyl Peptidase-4 inhibitor) to deliver dual, complementary action for optimal glycemic control in type 2 diabetes. Dapagliflozin reduces glucose reabsorption in the kidneys, enhancing urinary glucose excretion, aiding weight loss, and lowering blood pressure. Linagliptin prolongs incretin activity (glucagon- like peptide-1, glucose dependent insulinotropic polypeptide), boosting insulin secretion and suppressing glucagon in a glucose-dependent manner. It also offers cardio-renal protection by reducing albuminuria, cardiac hypertrophy, and fibrosis—making Glifiroz L ideal for patients with diabetes mellitus type II and associated cardio-vascular or renal risks.
• Packaging:1*10’S
• Therapy Area:Anti Diabetic Renal medicine